Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 26.77% ano a ano.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 2.32B.
Subavaliada
O PE mais recente da empresa é 16.62, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 270.87M ações, um aumento de 0.29% em relação ao trimestre anterior.
Mantido por James Simons
O Super Investidor James Simons possui 0.00 ações desta empresa.